July 8, 2021 Efferon managed to raise 200 million rubles in investments which were allocated by Fix Ventures IT, entrepreneur Dmitry Eremeev. As part of the deal, the company was valued at more than two billion rubles.

The Efferon project was established in 2016 by Ivan Bessonov and Alexei Morozov, graduates of the Chemistry Department of Moscow State University named after M.V. Lomonosov. In 2019, the Efferon® LPS and Efferon® CT disposable hemosorption columns were granted a permission for clinical use in Russia. Resuscitators use Efferon solutions as part of the comprehensive therapy of sepsis, septic shock, and severe forms of coronavirus infection. These solutions are based on a genuine technology for producing highly effective polymer sorbents for extracorporeal blood purification.

In 2020, Efferon entered into an agreement with the biopharmaceutical company Nanolek on collaboration efforts in the Russian market. The company is a resident of Skolkovo and the Moscow State University Science Park.

Alexander Volchansky, General Director of Efferon JSC:

“We managed to set up a full-cycle production of a globally competitive product. We focus on the rapidly growing demand in the domestic market, export deliveries to Latin America, the European Union, the Middle East, and China. Therefore, the immediate aim for 2021 is to scale up our production. In this connection, we welcome our new partner, Fix Ventures, and are glad to team up with him”.

Ivan Bessonov, technical director and co-founder of Efferon JSC:

“The global competitiveness of products like ours is evidential basis behind their purpose. It can be composed of two components. On the one hand, these are clinical research of a high level of evidence, like the LASSO multi-center randomized study initiated by us. On the other hand, it is “real-world evidence” and clinical research conducted in the form of “global registers.” We are confident that the competencies of the Fix Group in IT and big data analysis will help create a new value here both for our consumers and us. Our company needs advanced technology and continuous investment in research and development to stay ahead of the growing market. We plan to scale up investments in these fields further. In this matter, Dmitry Eremeev and I turned out to be like-minded people.”

Dmitry Eremeev, Founder of Fix Ventures and Bank 131:

“We are pleased to support a new Russian start-up with a truly global product. The Efferon team has created and continues to improve solutions that are already saving and will help save the lives of many more serious patients. We believe in the excellent prospects of Efferon in the Russian and global markets. Fix Ventures intends to continue to support the company’s growth in technological and financial perspective and its access to new markets and will keep investing in other fast-growing promising Russian companies.”

Oleg Movsesyan, Director of the Science Park of Moscow State University:

“I would like to congratulate our residents on a new round of investments - I’m sure that soon we will get the first “unicorn” represented by Efferon in our innovative company development ecosystem. The company has gone over a comparatively brief period from scientific development to a certified medical device that can successfully compete with the best world counterparts. The Science Park assisted in the preparation and conduct of clinical research of columns, in cooperation with the physicians of the Moscow State University Medical Center and several Moscow hospitals - first of all, State Hospital No. 67 named after L.A. Vorokhobov. We will be happy to use our competencies and contacts to successfully promote the company’s products in the world markets.”

Vladimir Khristenko, President of NANOLEK:

“It is important for us that Nanolek, which values its reputation and cooperates with the largest global pharmaceutical companies, has Efferon hemosorption columns in its portfolio. This is a completely Russian-made product with a solid evidence base, which is successfully used to treat sepsis. Over the past year, Efferon has quickly earned recognition from the leading resuscitators in Russia - it is used to treat severe forms of COVID-19. Since the pandemic, unfortunately, is not over yet, we are confident that this product will be in great demand. And we are ready to take active efforts for support of its development in the Russian market.”